A randomized clinical trial comparing 50mCi and 100mCi of iodine- 131 for ablation of differentiated thyroid cancers

Journal of the Pakistan Medical Association

Volumn 56, Issue 8, 2006, Pages 353-356

  Uz Zaman, Maseeh ^a   Toor, Rafia ^b   Kamal, Shahid ^a   Maqbool, Minhaj ^b   Habib, Salman ^a   Niaz, Khalid ^a  

^a Karachi Institute of Radiotherapy & Nuclear Medicine   (Pakistan)

^b JINNAH POSTGRADUATE MEDICAL CENTRE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; ARTICLE; BLOOD LEVEL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THYROID CANCER;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM, RESIDUAL; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33845527134     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cholewinksi SP, Yoo KS, Klieger PS, O'Mara RE. Absence of Thyroid stunning after diagnostic whole-body scanning with 185 MBq 13H. J Nucl Med 1991; 41:1198-1202.
2. Venecia CD, Germanier AG, Buston SR, Giovannini AA, Wyse EP. Hospital discharge of patients with thyroid carcinoma treated with 131I. J Nucl Med 2002; 43:61-65.
3. Parthasarathy KL, Crawford ES. Treatment of thyroid carcinoma: Emphasis on high-dose 131I outpatient therapy. J Nucl Med Tech 2002; 30:165-171.
4. Boone RT, Fan CY, Hanna EY. Well Differentiated Carcinoma of the thyroid. Otolaryngol Clin N Am 2003; 36:73-90.
5. Dorn R, Kopp J, Vogt H, Heindenreich P, Carrol RG, Gulec SA. Dosimetry guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44:451-56.
6. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89(4):1666-73.
7. Al-Nuaim AR, Ahmed M, Bakheet S, Abdul Kareem AM, Ingmenson S, Al-Ahmari et al. Papillary Thyroid Cancer in Saudi Arabia: Clinical, Pathologic and Management Characteristics. Clinical Nucl Med 1996; 21:307-11.
8. Toubert M, Michel C, Metivier F, Peker MC, Rain J. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis. Clinical Nucl Med 2001; 26:302-5.
9. Synder J, Gorman C, Scanlon P. Thyroid Remnant Ablation: Questionable Pursuit of an Ill-Defined Goal. J Nucl Med 1983; 24:659-65
10. Maxson HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Thinnefeld JD, Chen LS. Radioiodine-131 therapy fro well differentiated thyroid cancer: a quantitative radiation dosimetric approach outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-6.
11. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447-1463.
12. Thrall JH, Ziessman HA. Endocrine System. Mosby Inc. Missouri USA. 2001; pp 376.